Navigation Links
X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
Date:4/4/2013

WALTHAM, Mass. and LIANYUNGANG, China, April 4, 2013 /PRNewswire/ -- X-BODY BIOSCIENCES announced today an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), in which Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for Age-related Macular Degeneration (AMD) in Greater China (including mainland China, Taiwan, Macao, and Hong Kong).

Under the terms of the collaboration, Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts, for the Greater China markets.  X-BODY retains all development and commercialization rights outside of Greater China.  Detailed financial terms were not disclosed, but terms of the alliance include an upfront payment; clinical, regulatory and commercialization milestones; and royalties on revenues from commercialized products.

"It is an important part of our corporate strategy to partner with biotechs around the world that could provide interesting molecules for us to develop and commercialize, and we are excited to take on board the first of hopefully many development programs from X-BODY," said Lianshan Zhang, Ph.D., President of Global R&D, Jiangsu Hengrui Medicine Co., Ltd.

"This collaboration with Hengrui, the clear leader in pharmaceutical development in China, is an important step on our path to validate the capabilities of our DNA Display drug discovery platform.  We are encouraged to see our platform yield antibodies that could have a meaningful impact on patients' lives, especially for a disease as life-altering as AMD," added Julius Knowles , CEO of X-BODY.

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with annual R&D investment of over US$ 100 million. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with dozens of new molecular entities in clinical trials and under preclinical development.  Hengrui's products and R&D span over multiple therapeutic areas, such as oncology-hematology, anesthesiology, cardiovascular and metabolic diseases, ophthalmology, and inflammation. For more information, please visit http://www.hrs.com.cn/ and http://www.shhrp.com/.

About X-BODY Biosciences

X-BODY creates therapeutic antibodies against the most challenging and high-value drug targets, and is primarily focused on integral membrane proteins, such as GPCRs, ion channels, and transporters.  X-BODY is collaborating with leading biotech and pharmaceutical companies to progress its platform and its compounds.  X-BODY also generates antibodies internally, and has programs focused in oncology, ophthalmology, and metabolic diseases.  X-BODY is headquartered in Waltham, MA. For more information, please visit www.x-bodysciences.com


'/>"/>
SOURCE X-BODY BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argon Medical Devices Announces The Launch Of OptionELITE Retrievable Vena Cava Filter And The Acquisition of Angiotech Interventional Business
2. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
3. Akorn, Inc. Announces First Quarter 2013 Earnings Release And Conference Call Information
4. Dynamic Healthcare Services Announces David Erb as Director of Sales
5. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
6. Organovo Holdings, Inc. Announces Change of Fiscal Year
7. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
8. China Botanic Pharmaceutical Inc. Announces Receipt of Notice of Failure to Satisfy Continued Listing Letter
9. MD+DI Announces 46 Innovative Products as Finalists in 2013 Medical Design Excellence Awards
10. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the First Quarter Ended March 31, 2013
11. Research and Markets Announces the Release of Cellulose Ethers Market By Derivative & Application - Global Trends & Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a ... B-595 and B-7569 vinyl label materials received certification for the ... are tested to remain intact and legible, for use on chemical drums shipped by ...
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... ... April 21, 2017 , ... Westside Dental Associates ... dental care since 1985. After thirty-two years, Dr. Latner has become one of the ... my numerous clients over the years with all their dental needs,” said Dr. Latner, ...
Breaking Medicine News(10 mins):